The U.S. pharmaceutical industry seeks to alter Medicare drug price negotiation laws under Trump's return. China approves ...

Sarah Sammons, MD, discusses some of the challenges seen with different regimens for HER2-positive metastatic breast cancer ...

China: Enhertu, a blockbuster breast cancer drug of AstraZeneca, will be included in China's state-run health insurance ...

The latest health news includes studies on medications for thyroid issues and breast cancer, the healthcare industry's ...

AstraZeneca's (NASDAQ:AZN) blockbuster cancer medication, Enhertu, developed with Japanese pharma giant Daiichi Sankyo (OTCPK ...

AstraZeneca's blockbuster breast cancer drug will be added to China's national reimbursement scheme list, according to an ...

AstraZeneca's blockbuster breast cancer drug will be added to China's national reimbursement scheme list, according to an ...

China approved AstraZeneca Plc’s blockbuster breast cancer treatment for reimbursement by state-run medical insurance, a move ...

Returning for its 15th anniversary year, World ADC London is the leading European conference uniting over 1000 ADC ...

Founded in 2017 as a spin-out from the University of Copenhagen and Rigshospitalet, Adcendo previously raised $102.8m (€98m) ...

Today Monday 25th November, will be my 4th infusion of this dynamic combination of chemotherapy and an anti-cancer drug specifically designed ...

Commerce Bank increased its position in shares of AstraZeneca PLC (NASDAQ:AZN – Free Report) by 6.2% in the 3rd quarter, ...